Survival among older patients treated on the frontline HL study with sequential brentuximab vedotin and AVD chemotherapy. Kaplan-Meier curves at 2 years for (A) event-free survival (EFS; 80%; 95% CI, 65% to 89%), (B) progression-free survival (PFS; 84%; 95% CI, 69% to 92%), and (C) overall survival (OS; 93%; 95% CI, 80% to 98%) for all 48 patients. In addition, patients with a Cumulative Illness Rating Scale-Geriatrics (CIRS-G) score <10 had 2-year event-free survival (EFS), PFS, and OS rates of 100% (95% CI, 100% to 100%), and patients who had preserved functional status without loss of instrumental activities of daily living (IADL) at baseline had corresponding 2-year EFS, PFS, and OS rates of 89% (95% CI, 73% to 96%), 94% (95% CI, 79% to 99%), and 97% (95% CI, 82% to 99%), respectively. Reprinted with permission.¹⁹